Product nameAnti-Cleaved PARP1 antibody [4B5BD2]
See all Cleaved PARP1 primary antibodies
DescriptionMouse monoclonal [4B5BD2] to Cleaved PARP1
Specificityab110315 reacts with the N-terminal end formed by the cleavage adjacent to Asp214; it thus recognizes the apoptosis-specific 89 kDa catalytic domain fragment, but it does not recognize the full-length PARP1 or the 24 kDa DNA binding domain fragment.
Tested applicationsSuitable for: WB, ICC/IF, In-Cell ELISA, Flow Cytmore details
Species reactivityReacts with: Human
Synthetic peptide. This information is considered to be commercially sensitive.
- Staurosporine-treated HeLa and HL60 cells
This antibody clone is manufactured by Abcam.
This monoclonal antibody to cleaved PARP1 has been knockout validated in Western blot. The expected band for cleaved PARP1 was observed in wild type cells and the band was not seen in knockout cells.
Product was previously marketed under the MitoSciences sub-brand.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferPreservative: 0.02% Sodium azide
Constituent: HEPES buffered saline
Concentration information loading...
PurityAmmonium Sulphate Precipitation
Purification notesThe antibody was produced in vitro using hybridomas grown in serum-free medium, and then purified by ammonium sulfate precipiation.
Light chain typekappa
- Epigenetics and Nuclear Signaling
- DNA / RNA
- DNA Damage & Repair
- DNA Damage Response
- DNA Damage Recognition
Our Abpromise guarantee covers the use of ab110315 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.25 - 1 µg/ml. Predicted molecular weight: 113 kDa.|
|ICC/IF||Use a concentration of 1 µg/ml.|
|In-Cell ELISA||Use a concentration of 1 µg/ml.|
|Flow Cyt||Use a concentration of 1 µg/ml.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionInvolved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR. Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.
Sequence similaritiesContains 1 BRCT domain.
Contains 1 PARP alpha-helical domain.
Contains 1 PARP catalytic domain.
Contains 2 PARP-type zinc fingers.
modificationsPhosphorylated by PRKDC and TXK.
Poly-ADP-ribosylated by PARP2. Poly-ADP-ribosylation mediates the recruitment of CHD1L to DNA damage sites.
S-nitrosylated, leading to inhibit transcription regulation activity.
Cellular localizationNucleus. Nucleus, nucleolus. Localizes at sites of DNA damage.
- Information by UniProt
- ADP ribosyltransferase diphtheria toxin like 1 antibody
- ADP ribosyltransferase NAD(+) antibody
- ADP-ribosyltransferase diphtheria toxin-like 1 antibody
Lane 1: Wild type HAP1 (untreated) whole cell lysate (20 µg)
Lane 2: PARP1 (untreated) knockout HAP1 (untreated) whole cell lysate (20 µg)
Lane 3: HeLa (untreated) whole cell lysate (20 µg)
Lane 4: HAP1 (staurosporine treated, 1 uM, 4 hr) whole cell lysate (20 µg)
Lane 5: PARP1 (staurosporine treated, 1 uM, 4 hr) knockout HAP1 whole cell lysate (20 µg)
Lane 6: HeLa (staurosporine treated, 1 uM, 4 hr) whole cell lysate (20 µg)
Lanes 1 - 6: Merged signal (red and green). Green - ab110315 observed at 100 kDa. Red - loading control, ab181602, observed at 37 kDa
ab110315 detected the expected band for cleaved PARP1 in wild type HAP1 cells treated with staurosporine and the band was not seen in PARP1 knockout cells treated with staurosporine. Wild-type and PARP1 knockout samples were subjected to SDS-PAGE. ab110315 and ab181602 (Rabbit anti GAPDH loading control) were incubated overnight at 4°C at 1 ug/ml and 1/10000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed ab216772 and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed ab216777 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Immunocytochemistry images of stained untreated (A) and 4 hours 1 µM Staurosporine-treated (B) Human HeLa cells. The cells were paraformaldehyde fixed (4%, 20 minutes) and Triton X-100 permeabilized (0.1%, 15 minutes). The cells were incubated with 1.0 µg/ml ab110315 for 2 hours at room temperature or over night at 4°C. 10% goat serum was used as the blocking agent for all blocking steps. The secondary antibody was Alexa Fluor® 488 goat anti-mouse IgG (H+L) (in green) used at 2.0 µg/ml for 2 hours. DAPI was used to stain the cell nuclei (in red). Heat induced antigen retrieval (0.1 M Tris-HCl, 5% urea, pH 9.5 for 5 min at 95°C) improves signal. Note that the ab110315 labels only condensed and/or fragmented nuclei of apoptotic Staurosporine-treated cells.
Lanes 1-2 : Antibody that recognizes full-length PARP1
Lanes 3-4 : Anti-Cleaved PARP1 antibody [4B5BD2] (ab110315) at 1 µg/ml
Lanes 1 & 3 : untreated HeLa cells
Lanes 2 & 4 : HeLa cells treated with 1 µM Staurosporinefor 4 hours
Lysates/proteins at 20 µg per lane.
Predicted band size: 113 kDa
Western Blot analysis using ab110315 antibody and 20 µg of untreated (CON) or 4 hours 1 µM Staurosporine-treated (STS) HeLa cells. Blots were incubated with an antibody that recognizes both the full-length PARP1 and its 89 kDa fragment (left panel), or 1.0 µg/mL PARP1 (cleaved) antibody (ab110315) (right panel). Appropriate HRP-conjugated secondary antibodies followed by ECL detection were used. Note that the MS777 antibody recognizes the apoptosis-specific 89 kDa fragment of PARP1 but it does not recognize the full-length PARP1.
In-Cell ELISA (ICE) using ab110315 on HeLa cells treated with Staurosporine to induce apoptosis. HeLa cells were seeded overnight (50,000 cells/well), treated for 4 hours with 1 µM Staurosporine or with the drug vehicle (DMSO), fixed for Detaching Adherent Cells and analyzed.
Flow cytometry analysis of apoptosis using ab110315. HL-60 cells were treated with 1 µM Staurosporin for 4 hours (blue) or vehicle control (red). Control cells were also stained with an equal amount of an isotype control antibody (black).
This product has been referenced in:
- Hou Y et al. Genetic ablation of TAZ induces HepG2 liver cancer cell apoptosis through activating the CaMKII/MIEF1 signaling pathway. Onco Targets Ther 12:1765-1779 (2019). Read more (PubMed: 30881030) »
- Huang D et al. Oxaliplatin and infliximab synergize to induce regression of colon cancer. Oncol Lett 15:1517-1522 (2018). Read more (PubMed: 29434844) »